|
| Anadrol 50 oxymetholone : |
Anadrol 50 oxymetholone is the U.S. brand name for oxymetholone, a very potent oral androgen. Since oxymetholone is quite reliable in its ability to increase red blood cell production, it showed great promise in treating cases of severe anemia. It turned out to be well suited for this purpose, and was popular for quite some time.
Anadrol 50 oxymetholone drug is shown to have a much more direct effect on the red blood cell count, without the side effects of a strong androgen. Anadrol 50 is considered by many to be the most powerful steroid available, with results of this compound being extremely dramatic. A steroid novice experimenting with oxymetholone is likely to gain 20 to 30 pounds of massive bulk, and it can often be accomplished in less than 6 weeks, with only 50-100mg a day.
Oxymetholone is a derivative of dihydrotestosterone, which gives it a structure that cannot be aromatized. As such, many have speculated as to what makes this hormone so troublesome in terms of estrogenic side effects. However we do find medical studies looking at this possibility. One such tested the progestational activity of various steroids including nandrolone, norethandrolone, methandrostenolone, testosterone and oxymetholone.
Anadrol 50 oxymetholone is also a very potent androgen. This factor tends to produce many pronounced, unwanted androgenic side effects. Oily skin, acne and body/facial hair growth can be seen very quickly with this drug. Many individuals respond with severe acne, often requiring medication to keep it under control
|
Anadrol 50 is the very strongest and at the same time, also the most effective oral steroid. The Anadrol 50 compound has an extremely high androgenic effect, which goes hand in hand with an extremely intense anabolic component. For this reason, dramatic gains in strength and muscle mass can be achieved in a very short time. An increase in body weight of 10 - 15 pounds or more in only 14 days is not un-usual.
By the use of Anadrol 50, water retention is considerable, so that the muscle diameter quickly increases and the user gets a massive appearance within record time. Since the muscle cell draws a lot of water, the entire muscle system of most athletes looks smooth, in part even puffy. Anadrol does not cause a qualitative muscle gain but rather a quantitative one, which in the off-season is quite welcome.
Anadrol "lubricates" the joints since water is stored there as well. On the one hand this is a factor in the enormous increase of strength and, on the other hand, it allows athletes with joint problems a painless workout. Power lifters in the higher weight classes are sold on Anadrol. A strict diet, together with the simultaneous intake of Nolvadex and Proviron, can significantly reduce water retention so that a distinct increase in the solid muscles is possible.
By taking Anadrol the athlete experiences an enormous "pump effect" during the workout in the exercised muscles. The blood volume in the body is significantly elevated causing a higher blood supply to the muscles during workout. Anadrol increases the number of red blood cells, allowing the muscle to absorb more oxygen. The muscle thus has a higher endurance and performance level.
The highly androgenic effect of Anadrol stimulates the regeneration of the body so that the often-feared "over-training" is unlikely. Anadrol helps more than any other steroid during dieting to maintain the muscle mass and to allow an intense workout. Many bodybuilders therefore use it up to about one week before a competition, solving the problem of water retention by taking anti-estrogens and diuretics so that they will appear bulky and hard when in the limelight.
|
CBO: Biogenerics Would Save Federal Government $6.6 Billion Over
Ten YearsWASHINGTON, June 25, 2008 /PRNewswire-USNewswire/ -- The
Congressional Budget Office (CBO) today released a cost analysis
finding that the creation of an abbreviated pathway for follow-on
biologics -- or biogenerics -- would save the federal...
Center for Communication Compliance Launches First Regulatory
Resource, Training and Certification Portal for Healthcare
CommunicatorsGovernment fines of $6 billion imposed on pharmaceutical industry
for noncompliance
Standardized, centralized, expert-reviewed site helps reduce risk,
increase credibility, save time
NEW YORK, June 25, 2008
- The first and only...
Concerned Shareholders of Biovail Seek Court Order Declaring
Biovail AGM Illegally Convened;Say Biovail seeing tide changing against management - with six
million votes revoked - and no quoroum at meeting, secretly met to
change rules
TORONTO, June 25, 2008 /PRNewswire/ - The Concerned Shareholders
of Biovail said that their lawyers will...
New Report: The Truth About Drug InnovationNEW YORK, June 24, 2008- A new report co-authored by
Manhattan Institute senior fellow Benjamin Zycher, and Joseph
DiMasi, and Christopher-Paul Milne, researchers from the Tufts
Center for the Study of Drug Development, examines case...
Savings Help the Medicine Go DownPrescription drug coverage for low income seniors reduces Medicaid
WALTHAM, Mass., June 24, 2008—A new study of
state-subsidized pharmacy assistance programs showed that providing
prescription drug coverage for low-income seniors reduces...
Use of Drug-Releasing Stents Associated With Decrease in Repeat
Procedures to Unblock Coronary ArteriesCHICAGO, June 24, 2008—The widespread adoption of the use
of drug-releasing coronary artery stents into routine practice is
associated with a decrease in the need for repeat procedures to
unblock coronary arteries and also do not appear to...
Federal Action Needed to Fill Antibiotic Pipeline, Says the
Alliance for the Prudent Use of AntibioticsBOSTON, June 24, 2008 /PRNewswire-USNewswire/ -- Antibiotic
resistance is one of the major public health threats of the 21st
century and the focus of today's Senate hearing, Emergence of the
Superbug: Antimicrobial Resistance in the US. Resistant...
Center for Public Integrity: Drug Industry Spent Record Amount
Lobbying in '07 Over a Billion Dollars Spent in the Last 10 YearsWASHINGTON, D.C., June 24, 2008 - Pharmaceutical manufacturers
and their trade groups racked up another banner year on Capitol
Hill, spending a record $168 million on lobbying in 2007, a 32
percent jump over 2006, according to a Center for Public...
Barrier Therapeutics to Merge Into Stiefel LaboratoriesAcquisition to Enhance Industry Leader's Dermatological Portfolio
CORAL GABLES, Fla., June 23, 2008 /PRNewswire/ -- Stiefel
Laboratories Inc., the world's largest independent pharmaceutical
company specializing in dermatology, today announced it has...
FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral TaxaneClinical Studies Expected to Restart in Second Half 2008
BERKELEY HEIGHTS, N.J., June 23, 2008 /PRNewswire-FirstCall/ --
Genta Incorporated announced that the Company has received
notification from the U.S. Food and Drug Administration (FDA)...
GTC Biotherapeutics Enters Into $257 Million Agreement with Ovation
Pharmaceuticals to Develop and Market ATryn in the U.S.FRAMINGHAM, MA - June 23, 2008 -- GTC Biotherapeutics, Inc.
("GTC", Nasdaq: GTCB) and Ovation Pharmaceuticals, Inc.
(“OVATION”) have entered into a collaboration agreement
to develop and market ATryn in the United...
Should Doctors Be 'Selling' Drugs for the Pharmaceutical Industry?Feature: Key opinion leaders -- independent experts or drug
representatives in disguise?
LONDON, June 19, 2008-Are senior doctors who help drug companies
sell their drugs independent experts or just drug representatives
in disguise, asks Ray...
Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER
niacin/laropiprant) and MK-0524B (ER
niacin/laropiprant/simvastatin)WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Jun 20, 2008 - Merck
& Co., Inc. today provided an update on the regulatory status
in the United States of its investigational medicines MK-0524A (ER
niacin/ laropiprant) and MK-0524B...
YM BioSciences Announces FDA Lifts Clinical Hold on Aerolef and
Clearance of a Phase II Clinical Trial- Dr. Ali Raza To Lead Further Development Of AeroLEF As President
Of AeroLEF Division -
MISSISSAUGA, ON, June 19, 2008 /PRNewswire-FirstCall/ - YM
BioSciences Inc. , an oncology company that identifies, develops
and commercializes differentiated...
Canada's Research-Based Pharmaceutical Companies Invested Over a
Billion Dollars in Research and Development (R&D) in 2007 But
Opportunities Exist for Further Growth, Says Rx&DSAN DIEGO, CA, June 19 /CNW Telbec/ - Canada's Research-Based
Pharmaceutical Companies President Russell Williams issued the
following statement from BIO 2008 today in reaction to the release
of the Patented Medicine Prices Review Board's (PMPRB)...
Intas Biopharmaceuticals Ltd. Acquires US-based BPD Inc.SAN DIEGO--(BUSINESS WIRE)--Jun 20, 2008 - India's leading
biopharmaceutical company, Intas Biopharmaceuticals Ltd. (IBPL,
www.intasbiopharma.co.in), has acquired US-based biotechnology
corporation, Biologics Process Development Incorporated (BPD...
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic
Drugs Advisory Committee (DODAC) MeetingTHOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Jun
18, 2008 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a
division of Wyeth (NYSE: WYE), today issued the following statement
on the outcome of today's meeting of the U.S. Food...
Johnson & Johnson Nordic AB Acquires AmicGains Access to In Vitro Diagnostic Technologies in Development for
Use in Point-of-Care Settings
SOLLENTUNA, Sweden, June 18, 2008 /PRNewswire/ -- Johnson &
Johnson Nordic AB, a Johnson & Johnson company, today announced
the acquisition of...
Majority of Americans Support Legislative Action to Disclose
Pharmaceutical Company Gifts to PhysiciansBOSTON--(BUSINESS WIRE)--Jun 18, 2008 - A majority of Americans
(64%) say that it is important to know their physician's financial
ties to pharmaceutical companies and 68% would support legislation
requiring pharmaceutical companies to disclose...
Singapore Reinforces Position as a Global Site for Pharma &
Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17
BillionSophisticated Infrastructure and Skilled Manpower Support
Cutting-Edge Manufacturing Activities
SAN DIEGO, June 18, 2008 /Xinhua-PRNewswire/ -- Singapore has
firmly established itself as a leading manufacturing hub in Asia
with its strong track...
EMEA Recommends Information on Lung Cancer Cases to Be Included in
Exubera Product InformationLONDON, 17
June 2008--The
European Medicines Agency (EMEA) has recommended that the product
information for Exubera be updated with new information on cases of
lung cancer seen in patients taking the medicine. Exubera, from
Pfizer Limited, is a...
Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino
Review Period for Acquisition of Kosan Biosciences IncorporatedPRINCETON, N.J.--(BUSINESS WIRE)--Jun 18, 2008 - Bristol-Myers
Squibb Company (NYSE: BMY) announced today that the
Hart-Scott-Rodino review period for its tender offer for Kosan
Biosciences Incorporated (NASDAQ: KOSN) ("Kosan") has...
FDA Warns Individuals and Firms to Stop Selling Fake Cancer 'Cures'Fraudulent claims on Internet sites
ROCKVILLE, Md., June 17, 2008--Warning Letters have been sent to
23 U.S. companies and two foreign individuals marketing a wide
range of products fraudulently claiming to prevent and cure cancer,
according to...
FDA Advisory Committee Unanimously Recommends Approval of
Ustekinumab for Treatment of Moderate to Severe Plaque PsoriasisHORSHAM, Pa., June 17, 2008 /PRNewswire/ -- Centocor, Inc.
announced today that the Dermatologic and Ophthalmic Drugs Advisory
Committee (DODAC) of the U.S. Food and Drug Administration (FDA)
has unanimously recommended the approval of ustekinumab,...
Ranbaxy and Pfizer Settle Lipitor Litigation WorldwideRanbaxy Will Market Generic Atorvastatin in the U.S. With 180 Days
Exclusivity From Nov. 30, 2011
GURGAON, Harayana, India and PRINCETON, N.J., June 18, 2008
/PRNewswire/ -- Ranbaxy Laboratories Limited (Ranbaxy), announced
today that it has entered...
Sanofi-aventis Intends to Make a Competing Bid of CzK 1,050 in Cash
Per Share for ZentivaPARIS, France, June 18, 2008 - Sanofi-aventis
intends to make a Competing Bid for all issued and outstanding
ordinary shares in the share capital of Zentiva at an offer price
of CZK 1,050 in cash per Share. The Competing Bid values Zentiva at
40,043...
Statement Regarding Official Publication of Voluntary Takeover
Offer by Anthiarose LimitedZentiva N.V.
PRAGUE, CZ and LONDON, June 17, 2008 - Zentiva N.V.
notes the official publication today by Anthiarose Limited, a
wholly owned subsidiary of PPF Group N.V., of its unsolicited
voluntary takeover offer to acquire Zentiva N.V....
Novartis, Pfizer and Merck Take the Lead on Strong Relationships
with Physicians, as Doctors Demand an Expanding Set Of ServicesNEW YORK, June 17, 2008— Among US
primary care physicians, Novartis earns the highest sales rep
relationship scores, followed by Pfizer, Merck, GlaxoSmithKline and
Sanofi-Aventis, according to new research from TNS Healthcare.
Novartis...
Decision Resources, Inc. Acquires Manhattan ResearchAcquisition Expands Decision Resources, Inc.'s Portfolio to Include
Global Physician and Consumer Digital Market Research
WALTHAM, Mass. and NEW YORK, June 17, 2008 /PRNewswire/ --
Decision Resources, Inc., one of the world's leading research...
Reps. Dingell, Stupak Welcome PhRMA Invitation to Discuss DTC
RegulationsWASHINGTON, June 16, 2008-Leaders of the Committee on Energy and
Commerce today responded to four pharmaceutical companies and their
trade association regarding their business practices related to
Direct-to-Consumer (DTC) advertising. On May 20,...
Boehringer Ingelheim to Acquire Actimis PharmaceuticalsINGELHEIM, Germany, SAN DIEGO, United States, June 17, 2008 -
Boehringer Ingelheim GmbH today announced an agreement to acquire
Actimis Pharmaceuticals, Inc., a privately owned biotech company
based in San Diego. The acquisition will occur through a...
IMS Health Reports Global Biotech Sales Grew 12.5 Percent in 2007,
Exceeding $75 BillionNORWALK, Conn.--(BUSINESS WIRE)--June 17, 2008--Global
prescription sales of biotech drugs increased 12.5 percent in 2007
to more than $75 billion, according to a new report by IMS Health
(NYSE: RX), the world's leading provider of market...
FDA Requests Boxed Warnings on Older Class of Antipsychotic DrugsROCKVILLE, Md., June 16, 2008--The U.S. Food and Drug
Administration today exercised its new authority under the Food and
Drug Administration Amendments Act of 2007 (FDAAA) to require
manufacturers of "conventional" antipsychotic drugs to...
Information for Healthcare Professionals: AntipsychoticsROCKVILLE, Md., June 16, 2008-FDA ALERT
[6/16/2008]: FDA is notifying healthcare professionals that
both conventional and atypical antipsychotics are associated with
an increased risk of mortality in elderly patients treated...
Biovail Recommends Shareholders Vote to Move Forward from the
Melnyk Lost YearsTORONTO--(BUSINESS WIRE)--Jun 16, 2008 - Biovail Corporation
(NYSE:BVF)(TSX:BVF) today issued a second letter to shareholders,
reminding them of the impending deadline to vote for the Biovail
nominees to the Board of Directors at the Company's June...
Ore Pharmaceuticals Focuses Resources on Development of
Repositioned CompoundsGAITHERSBURG, Md.--(BUSINESS WIRE)--Jun 16, 2008 - Ore
Pharmaceuticals Inc. (NASDAQ:ORXED) announced today a new alignment
of corporate resources. Henceforward, the Company will invest its
resources in clinical development and business development...
Novartis Vaccines and Diagnostics S.r.l. Withdraws Its Marketing
Authorisation Application for the Pre-pandemic Vaccine AflunovLONDON, June 16, 2008-The European Medicines Agency (EMEA) has
been formally notified by Novartis Vaccines and Diagnostics S.r.l.
of its decision to withdraw the application for a centralised
marketing authorisation for the pre-pandemic vaccine...
Drug Makers Differ Strongly in Policies for Low-income CountriesIndex lets investors select most socially responsible
producers
HAARLEM, THE NETHERLANDS (June 16, 2008) — The world's
largest pharmaceutical companies differ strongly in their efforts
to provide millions of people in low-income...
Sen. Grassley Seeks FDA Scrutiny of Paxil and Suicide RiskWASHINGTON, June 12, 2008 - Senator Chuck Grassley
has asked the Food and Drug Administration to carefully scrutinize
information it received from drug maker GlaxoSmithKline about the
anxiety disorder drug Paxil, based on the contents of a...
FDA, European Medicines Agency to Consider Additional Test Results
When Assessing New Drug SafetyCollaborative Effort by FDA and EMEA Expected to Yield
Additional Safety Data
ROCKVILLE, Md., June 12, 2008--In the first use of a framework
allowing submission of a single application to the two agencies,
the Food and Drug Administration (FDA) and...
|
|
|
|